Recent advances in the management of Crohn's disease

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
R CaprilliV Clemente

Abstract

In the last 10 years many advances have been achieved in the treatment of patients with Crohn's disease, particularly in the field of biological agents. Infliximab, a tumour necrosis factor alpha antagonist, has been recently added to the therapeutic armamentarium for Crohn's disease and has greatly improved our treatment options. Infliximab has demonstrated efficacy in the induction and maintenance of remission in luminal and fistulizing Crohn's disease both in adults and children. However, the potential development of autoantibodies and the risk of serious adverse events limit the possibility of a wider use of infliximab. Searching for less immunogenicity and higher effectiveness in the last years a number of biological agents have been developed. Adalimumab, a fully human monoclonal antibody anti tumour necrosis factor alpha, has resulted effective and safe in patients with Crohn's disease, both naive and refractory to infliximab, presenting also the advantage of subcutaneous way of administration. Natalizumab also showed promising results in terms of efficacy but its safety is still under investigation. To date no particular advances have been recently appeared in the literature concerning conventional immunosuppressive dru...Continue Reading

References

Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
May 6, 2004·Scandinavian Journal of Gastroenterology·T BernklevUNKNOWN IBSEN Study Group
Mar 26, 2005·International Archives of Occupational and Environmental Health·K RoskesJ W J van der Gulden
Sep 7, 2005·Gastroenterology·Stefan SchreiberUNKNOWN CDP870 Crohn's Disease Study Group
Jan 31, 2006·Alimentary Pharmacology & Therapeutics·P RutgeertsS Vermeire
Mar 3, 2006·The New England Journal of Medicine·Tarek A YousryDavid B Clifford
Dec 26, 2006·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·L P L GilissenL G J B Engels
Jan 27, 2007·Journal of Pediatric Gastroenterology and Nutrition·Ann Corken MackeyMark Avigan
May 9, 2007·Gastroenterology·Stephan R TarganUNKNOWN International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group
Jun 5, 2007·Current Opinion in Gastroenterology·Bas Oldenburg, Daan Hommes
Jun 30, 2007·Inflammatory Bowel Diseases·Garret CullenDiarmuid P O'donoghue
Jul 17, 2007·Medicine·Manuel Ramos-CasalsMunther A Khamashta
Aug 24, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·J DalmauA Alomar
Sep 1, 2007·Nature Clinical Practice. Rheumatology·Christoph LangeStefan Ehlers
Sep 12, 2007·Birth Defects Research. Part A, Clinical and Molecular Teratology·Lee Hilary GoldsteinMatitiahu Berkovitch
Nov 21, 2007·Inflammatory Bowel Diseases·Arun Swaminath, Simon Lichtiger
Dec 12, 2007·World Journal of Gastroenterology : WJG·Emanuele RondonottiRoberto de Franchis
Dec 18, 2007·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·N K H de BoerC J J Mulder

❮ Previous
Next ❯

Citations

Nov 20, 2012·Journal of Crohn's & Colitis·Achuthan SourianarayananeBo Shen
Jun 18, 1999·Gastroenterology Clinics of North America·V Raj, D R Lichtenstein
May 19, 2010·Expert Review of Clinical Immunology·Danial E Baker
Feb 23, 2010·Translational Research : the Journal of Laboratory and Clinical Medicine·Hiroshi KonoMasahito Ogiku
May 5, 2012·The British Journal of Surgery·B MalgrasK Pautrat
Jul 15, 2015·Annals of Medicine and Surgery·Anna Weiss, Bryan Sandler
May 10, 2013·ACS Synthetic Biology·Eric J ArcherGürol M Süel
Aug 15, 2009·Journal of Pediatric Gastroenterology and Nutrition·Elena ChiappiniPaolo Lionetti
Apr 17, 2020·Frontiers in Bioengineering and Biotechnology·Maria BarraDaniel Garrido

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
W FriesL Familiari
Therapeutic Advances in Gastroenterology
Gary R LichtensteinGordon Mallarkey
Journal of Hepatology
C S Lieber, L DeCarli
© 2022 Meta ULC. All rights reserved